Zhengzhou Major Pig Disease Prevention and Control Laboratory, College of Veterinary Medicine, Henan Agricultural University, Zhengdong New District Longzi Lake 15#, Zhengzhou 450046, People's Republic of China.
College of Veterinary Medicine, Henan University of Animal Husbandry and Economy, Zhengzhou 450046, People's Republic of China.
Infect Genet Evol. 2021 Aug;92:104835. doi: 10.1016/j.meegid.2021.104835. Epub 2021 Mar 31.
In late 2011, the outbreak of pseudorabies (PR) occurred in Bartha-K61-vaccinated pig farms and spread rapidly to many provinces of China, causing substantial economic losses to the swine industry. A total of 4708 pig serum samples from Henan province during 2018-2019 were collected to screen for the presence of pseudorabies virus (PRV) gE-specific antibodies, and phylogenetic analysis based on the gE gene of PRV was performed. Of the 4708 serum samples tested, 30.14% (1419/4708) were seropositive for PRV antibodies, based on PRV gE-coated enzyme-linked immunosorbent assay (ELISA), with slaughterhouses having the highest seroprevalence. The seropositive rates of PRV also varied with the region and the season. Phylogenetic analysis showed that three PRV isolates from this study were clustered in an independent branch together with the Chinese variant PRV strains (after 2012), and had a closer genetic relationship with the Chinese variant PRV strains, but differed genetically from the 4 early Chinese PRV strains and 4 European-American strains. This study suggests that three PRV isolates may belong to PRV variants, and the development of a novel vaccine against PRV variants is particularly urgent.
2011 年末,猪伪狂犬病(PR)在使用 Bartha-K61 疫苗免疫的猪场暴发,并迅速传播至中国多个省份,给养猪业造成了巨大的经济损失。本研究于 2018-2019 年期间采集了河南省 4708 份猪血清样品,用于检测猪伪狂犬病病毒(PRV)gE 特异性抗体,并对 PRV gE 基因进行了系统进化分析。基于 PRV gE 包被酶联免疫吸附试验(ELISA)检测结果,30.14%(1419/4708)的血清样品呈 PRV 抗体阳性,其中屠宰场的阳性检出率最高。PRV 的血清阳性率还随地区和季节的不同而变化。系统进化分析表明,本研究中的 3 个 PRV 分离株与中国变异株 PRV(2012 年后)聚为一个独立分支,与中国变异株 PRV 的亲缘关系更近,但与 4 个早期中国 PRV 株和 4 个欧美株在遗传上存在差异。本研究提示,这 3 个 PRV 分离株可能属于 PRV 变异株,因此迫切需要开发针对 PRV 变异株的新型疫苗。